BioStem Technologies, Inc. · NASDAQ:BSEM
BioStem Technologies — Investor Presentation (April 2026)
20 slides from BioStem Technologies's investor presentation, April 2026
Slide 1: Company Presentation
Company Presentation APRIL 2026
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation includes “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, without limitation, certain statements, estimates and projections provided by BioStem Technologies,
Slide 3: Our Mission
To create and deliver the most Our advanced wound healing technologies in the world Mission In Relentless Pursuit of Healing
Slide 4: Investment Highlights
Investment Highlights Driving adoption of perinatal tissue allografts Differentiated Technology Strong Foundation Growth Engine 3 Industry-Leading Technologies Existing Manufacturing Capabilities Expansion of Addressable Market BioRetain®, CryoTek® and SteriTek® Experienced in-house manufacturing wi
Slide 5: The Need for Perinatal Allografts
The Need for Perinatal Allografts Regenerative Medicine promotes faster healing and reduces complications* Faster Healing Economic Impact1 Perinatal allografts maintain an optimal healing environment, accelerating tissue regeneration Infections and complications cost the Infection Prevention health
Slide 6: Large and Underserved ~$23B US Soft Tissue Allograft Opportunity
Large and Underserved ~$23B US Soft Tissue Allograft Opportunity Driving adoption of perinatal tissue allografts for multiple market segments 1 Orthopedics/Sports Medicine 4 Urology/ Colorectal US TAM: ~$2.3B US TAM: ~$1.5B Knee Osteoarthritis | Soft Tissue Radical Prostatectomy | Urethral / Repair|
Slide 7: Stronger Platform for the Next Phase of Growth
Stronger Platform for the Next Phase of Growth Diversifying End Markets Differentiating Product Portfolio • Expanding into additional sites of care, patient • Expanding capabilities across multiple tissue formats populations, and procedural applications • Increasing versatile technology stack across
Slide 8: Our Regenerative Medicine Solutions
Our Regenerative Medicine Solutions A complete portfolio of perinatal tissue allografts Orthopedics/Sports Medicine · Foot & Ankle · Urology / Colorectal · Chronic Wound Care NON-WOUND / SURGICAL WOUND Spine · Women's Health Clarix 1K Clarix 100 Clarix Flo Neox 1K Neox 100 Neox RT Cryopreserved amni
Slide 9: Product Roadmap
Product Roadmap Utilize regulatory approvals to strengthen claims, enhance product marketability and expand payor coverage Organic BioRetain VendajeAC Launched Launched 2021 2022 2026 2026(E) Neox & Clarix Catalyze Acquired 510(k) Inorganic 9
Slide 10: BioStem Regenerative Technology Platforms
BioStem Regenerative Technology Platforms Best in class platforms that preserve the natural properties of perinatal tissue to create leading allografts The patented six-step BioRetain® process is gentle, minimally invasive, and preserves the natural integrity of the amniotic tissue/ components criti
Slide 11: BioRetain Optimizes Retention of Natural Tissue Properties
BioRetain® Optimizes Retention of Natural Tissue Properties Demonstrated superiority over market leader IL-1ra P D GF -BB H ya l u r o n a n Collagen 1a1 5.0E+07 4.84E+07 4.0E+04 38547.5908 1.83E+03 3.5E+04 33609.815 4.0E+07 Concentration pg/cm2 3.0E+04 25197.6752 2.5E+04 3.0E+07 2.0E+04 2.0E+07 1.5
Slide 12: Results of DFU and Ambulate Studies
Results of DFU and Ambulate Studies Multiple robust randomized control trials supporting the technology Superior Outcomes with BioRetain® Ambulate Study2 Allograft in Diabetic Foot Ulcers1 • Trial design to meet the most rigorous patient • Trial design to treat the most severe selection and clinical
Slide 13: Expanding to Multi-Channel Commercial Infrastructure
Expanding to Multi-Channel Commercial Infrastructure Independent Sales Agents & Distributors Direct GPO Distributors • Leverage current • Establish relationship • Premier, relationship with Vizient, HPG • Leverage current with physician champion relationships Venture • Process to • Gain access to •
Slide 14: Expanding Payor Mix Towards Commercial Reimbursement
Expanding Payor Mix Towards Commercial Reimbursement Compelling unit economics in the hospital setting Physician Office Hospital Market Market Vendaje Neox, Clarix CMS Payor Commercial Payor 14 14
Slide 15: Multiple Commercial Growth Levers
Multiple Commercial Growth Levers EXPAND CHANNEL & GEOGRAPHIC FOOTPRINT DRIVE ADOPTION WITH PEER-to-PEER SELLING INCREASE PAYOR COVERAGE AND PATIENT ACCESS EXECUTING PRODUCT ROAD MAP Primary revenue generating states Opportunities for growth 15
Slide 16: World-Class Manufacturing
World-Class Manufacturing AATB® accredited, cGTP facility State of the art, vertically integrated manufacturing facility Currently processing 30k sq cm monthly Capacity up to 100K sq cm monthly to support future growth 6,100 sq ft dedicated area; 3,000 sq ft ISO clean room space Located in Pompano B
Slide 17: Management Team
Management Team Accomplished team with deep industry experience Jason Matuszewski LSSBB Andrew Van Vurst CTBS Brandon Poe Michael Fortunato CPA Barry Hassett Chief Executive Officer Chief Operating Officer Chief Financial Officer Chief Accounting Officer Chief Commercial Officer Noah Agron Wendy Wes
Slide 18: Financial Outlook
Financial Outlook Strong Financial Investing for growth in our surgical revenue base; Acquired assets generated $29M in 2025 and largely unaffected by CMS price changes Profile Transition period for wound business in 1H 2026 as market digests CMS payment changes Efficient manufacturing process (and
Slide 19: Well-Positioned to Capitalize on Opportunities in Perinatal Allografts
Well-Positioned to Capitalize on Opportunities in Perinatal Allografts Generating Evidence Diversifying Portfolio Driving Growth • Complete the remaining VLU and DFU • BioTissue acquisition diversifies the • Large, growing market with significant RCTs in 2026 to strengthen clinical product portfolio
Slide 20: Thank you
Thank you MARCH 2026 BSEM
BioStem Technologies — Investor Presentation (April 2026) on 6ix